A New Biotech ETF Targets Companies In Late Stage Clinical Trials

ETF providers seem eager to take advantage of the popularity of biotechs recently. The biotech sector as measured by the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) was up 34% in 2014 and has seen its assets more than double in the past 18 months. In addition, five new biotech ETFs have been launched since the end of 2014 and four of them are targeting unique niches within the biotech universe. I covered one of those ETFs - the BioShares Biotechnology Clinical Trials ETF (NASDAQ:BBC) - recently and now another specialty biotech ETF has hit the market.

 

The ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) launched on December 31, 2014 and is targeting biotech and pharmaceutical companies that have one or more drugs currently in later stage clinical trials. According to the fund's fact sheet, the company needs to meet the following criteria in order to be considered for inclusion in the ETF:

Click the button below to read the rest of this original article on Seeking Alpha.

ETF Research

We cover ETFs across all sectors, regions and markets. We analyze the portfolios themselves as well as the macro environments that affect them.

Mutual Fund Research

We do mutual fund research too! Although not covered quite as in-depth as the ETF world, we've still profiled many of the big names!

Investing Strategy

Everything from retirement planning to 401(k) investing to options trading strategies and everything in between!

Next Steps...

Got a question? A comment? A fund you want to see profiled? Let us know!

Subscribe to receive the ETF Focus Weekly newsletter absolutely FREE!

* indicates required




Be the first to comment

Leave a Reply

Your email address will not be published.


*